Gilead’s expansion is expected to create approximately 800 direct high-skilled positions in the biopharmaceutical sector while supporting an additional 2,200 indirect jobs across supplier networks and local economies by 2028. This workforce development initiative builds on the company’s established track record of U.S. investment, having deployed $15 billion in domestic operations over the past decade that has positioned Gilead as a leader in antiviral and oncology therapeutic development.
Strengthening Domestic Biopharma Infrastructure
The capital infusion will accelerate development of innovative medicines while reinforcing America’s pharmaceutical manufacturing independence. By concentrating investments in domestic facilities, Gilead aims to shorten development timelines for critical therapies and establish more resilient supply chains for essential medications, particularly in virology and cancer treatment where the company maintains market leadership.
Long-Term Industry Leadership Commitment
This multi-year investment strategy demonstrates Gilead’s commitment to maintaining technological leadership in biopharmaceutical innovation while contributing to U.S. economic growth. The planned facility expansions and technology upgrades will ensure the company remains competitive in developing complex therapeutics, with particular focus on areas of unmet medical need that align with national health priorities.
Related Topics: